RESEARCHER PROFILE

Aditya Bardia

← Back to University of California, Los Angeles

A

University of California, Los Angeles

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesCancer Genomics and DiagnosticsPARP inhibition in cancer therapyBRCA gene mutations in cancer

Aditya Bardia works in Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, BRCA gene mutations in cancer. Recorded institutional associations include Harvard University, University of California, Los Angeles, Universidade de São Paulo.

1,252Publications
41,023Citations
90H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    2013 · 2,469 citations
  2. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

    2014 · 2,441 citations
  3. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

    2020 · 1,725 citations
  4. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    2021 · 1,688 citations
  5. Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

    2013 · 1,086 citations
  6. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    2018 · 1,016 citations
  7. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    2019 · 998 citations
  8. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

    2020 · 938 citations
  9. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    2014 · 913 citations
  10. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    2019 · 869 citations
  11. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    2022 · 757 citations
  12. A microfluidic device for label-free, physical capture of circulating tumor cell clusters

    2015 · 709 citations
  13. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

    2018 · 530 citations
  14. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

    2007 · 503 citations
  15. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    2023 · 488 citations
  16. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

    2024 · 485 citations
  17. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

    2020 · 468 citations
  18. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells

    2021 · 418 citations
  19. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

    2021 · 414 citations
  20. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    2017 · 412 citations
  21. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    2019 · 408 citations
  22. HER2 expression identifies dynamic functional states within circulating breast cancer cells

    2016 · 406 citations
  23. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    2024 · 405 citations
  24. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    2021 · 400 citations
  25. Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

    2016 · 394 citations

← Return to the university profile